Rodin Therapeutics

DIscovering First-in-Class Therapeutics for the Advancement of Neurological Disorder Treatment

  • CEO: Adam Rosenberg
  • Location: Cambridge, MA
  • Milestones: Sept 2017 - Third Point Ventures initial investment, Nov 2019 - Rodin Therapeutics acquired by Alkermes (NASDAQ: ALKS)
Go to site

Rodin Therapeutics is discovering and developing first in class therapeutics for neurological disorders.